Apolipoprotein E: A Potent Gene-Based Therapeutic Target for the Treatment of Sporadic Alzheimer's Disease
Publisher
Springer New York
Reference43 articles.
1. Aleong, R., Aumont, N., Dea, D., & Poirier, J. (2003). Non-steroidal anti-inflammatory drugs mediate increased in vitro glial expression of apolipoprotein E protein. European Journal of Neuroscience, 18, 1428–1438. 2. Allen, S. J., MacGowan, S. H., Tyler, S., Wilcock, G. K., Robertson, A. G., Holden, P. H., et al. (1997). Reduced cholinergic function in normal and Alzheimer's disease brain is associated with apolipoprotein E4 genotype. Neuroscience Letters, 239, 33–36. 3. Arendt, T, Schindler, C., Bruckner, M. K., Eschrich, K., Bigl, V., Zedlick, D., et al. (1997). Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele. The Journal of Neuroscience, 17, 516–529. 4. Beffert, U., Aumont, N., Dea, D., Lussier-Cacan, S., Davignon, J., & Poirier, J. (1999). Apolipoprotein E isoform-specific reduction of extracellular amyloid in neuronal cultures. Brain Research. Molecular Brain Research, 68, 181–185. 5. Beffert, U., & Poirier, J. (1996). Apolipoprotein E, plaques, tangles and cholinergic dysfunction in Alzheimer's disease. Neurobiology of Alzheimer's Disease, 777, 166–174.
|
|